Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply injection pens for Danish drugmaker’s next-gen obesity therapy CagriSema, Reuters reported Friday, citing a source familiar with the matter.

The report indicates the company’s long-term commercial plans for the once-weekly injectable, which is currently undergoing late-stage clinical development and expected to generate Phase 3 data this year.

CagriSema is designed by combining semaglutide, the active ingredient of Novo’s (NVO) popular weight loss therapy, Wegovy, with another compound mimicking a metabolic hormone called amylin.

Novo (NVO) expects it to generate 25% of average weight loss within a year, compared to Wegovy’s 15% and 20% achieved by its rival weight loss therapy Zepbound developed by Eli Lilly (LLY). Spokespersons for Novo (NVO) and Ypsomed (OTCPK:YPHDF) declined to comment.

Last year, Ypsomed (OTCPK:YPHDF) inked a long-term agreement to supply Novo (NVO) with autoinjectors designed to deliver self-administered therapeutics for multiple metabolic conditions.